Skip to main content
Equibles
PAYS logo

PAYS · Paysign, Inc. · Webcasts, Transcripts & Audio

Track PAYS — free

Use PAYS with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research PAYS.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$14.46 +0.49 (+3.51%) Q2 2026 earnings call transcript
Russell 2000 member Rebalance outlook locked
Market Cap
$788.78M
Shares
56.46M
Volume · Oct 29 186.03K Avg daily vol (3M) 823.44K

Paysign, Inc. Webcasts

Earnings calls, investor updates, investor days and conferences for Paysign, Inc. (PAYS), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.

Pull transcripts and briefs through the earnings call transcript API or MCP → Add these events to your calendar (.ics)
Earnings call
FY26 · Q2
2026-08-05
Paysign, Inc. (PAYS) Q2 2026 Earnings Call Transcript
Confident tone Plasma business recovery Patient affordability growth Margin expansion and operating leverage
Revenue
$28.25M
▲ 48.1% YoY
Diluted EPS
$0.11
▲ 450% YoY
Gross margin
63.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY26 · Q1
2026-05-12
Paysign, Inc. (PAYS) Q1 2026 Earnings Call Transcript
Confident tone Plasma donor compensation Patient affordability / pharma growth Pipeline and program additions
Revenue
$28.04M
▲ 50.8% YoY
Diluted EPS
$0.09
▲ 80% YoY
Gross margin
65.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-03-24
Paysign, Inc. (PAYS) Q4 2025 Earnings Call Transcript
Confident tone Patient Affordability Growth Plasma Donor Compensation Dynamic Business Rules / Maximizer Solution
Revenue
$22.76M*
▲ 45.8% YoY
Gross margin
57.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-12
Paysign, Inc. (PAYS) Q3 2025 Earnings Call Transcript
Confident tone Patient Affordability Growth Plasma Donor Compensation Revenue Mix and Seasonality
Revenue
$21.60M
▲ 41.6% YoY
Diluted EPS
$0.04
▲ 33.3% YoY
Gross margin
56.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-05
Paysign, Inc. (PAYS) Q2 2025 Earnings Call Transcript
Confident tone Patient affordability / pharma growth Revenue mix and program economics Profitability and margin expansion
Revenue
$19.08M
▲ 33.1% YoY
Diluted EPS
$0.02
▲ 100% YoY
Gross margin
61.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-08
Paysign, Inc. (PAYS) Q1 2025 Earnings Call Transcript
Confident tone Financial performance and profitability 2025 guidance and outlook Gamma acquisition and integration
Revenue
$18.60M
▲ 41% YoY
Diluted EPS
$0.05
▲ 400% YoY
Gross margin
62.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-03-25
Paysign, Inc. (PAYS) Q4 2024 Earnings Call Transcript
Confident tone Plasma donor compensation Patient affordability (pharma) growth Operating leverage and margins
Revenue
$15.61M*
▲ 14% YoY
Gross margin
58.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-05
Paysign, Inc. (PAYS) Q3 2024 Earnings Call Transcript
Confident tone Patient affordability growth Revenue and profitability Competitive positioning and IP
Revenue
$15.26M
▲ 23% YoY
Diluted EPS
$0.03
▲ 50% YoY
Gross margin
55.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-07-31
Paysign, Inc. (PAYS) Q2 2024 Earnings Call Transcript
Confident tone Patient Affordability Growth Revenue and Profitability SG&A and Hiring Investment
Revenue
$14.33M
▲ 29.8% YoY
Diluted EPS
$0.01
Gross margin
52.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-07
Paysign, Inc. (PAYS) Q1 2024 Earnings Call Transcript
Confident tone Patient Affordability Growth Financial Performance Drug Exclusivity / Generics Risk
Revenue
$13.19M
▲ 30% YoY
Diluted EPS
$0.01
Gross margin
52.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-03-26
Paysign, Inc. (PAYS) Q4 2023 Earnings Call Transcript
Confident tone Patient Affordability Growth Financial Performance Plasma Donor Compensation
Revenue
$13.69M*
▲ 28.9% YoY
Gross margin
52.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-07
Paysign, Inc. (PAYS) Q3 2023 Earnings Call Transcript
Revenue
$12.40M
▲ 17% YoY
Diluted EPS
$0.02
▲ 0% YoY
Gross margin
51.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-08
Paysign, Inc. (PAYS) Q2 2023 Earnings Call Transcript
Revenue
$11.04M
▲ 28.4% YoY
Diluted EPS
$0.00
Gross margin
50.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-10
Paysign, Inc. (PAYS) Q1 2023 Earnings Call Transcript
Revenue
$10.14M
▲ 23.4% YoY
Diluted EPS
$0.00
Gross margin
49.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-03-22
Paysign, Inc. (PAYS) Q4 2022 Earnings Call Transcript
Revenue
$10.62M*
▲ 21.1% YoY
Gross margin
51.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-08
Paysign, Inc. (PAYS) Q3 2022 Earnings Call Transcript
Revenue
$10.60M
▲ 36.4% YoY
Diluted EPS
$0.02
Gross margin
54.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-09
Paysign, Inc. (PAYS) Q2 2022 Earnings Call Transcript
Revenue
$8.60M
▲ 29.3% YoY
Diluted EPS
$0.00
Gross margin
54.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-11
Paysign, Inc. (PAYS) Q1 2022 Earnings Call Transcript
Revenue
$8.22M
▲ 30.9% YoY
Diluted EPS
$-0.01
Gross margin
60.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-03-22
Paysign, Inc. (PAYS) Q4 2021 Earnings Call Transcript
Revenue
$8.77M*
▲ 20.9% YoY
Gross margin
54.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-11-09
Paysign, Inc. (PAYS) Q3 2021 Earnings Call Transcript
Revenue
$7.77M
Diluted EPS
$-0.01
Gross margin
51.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-08-10
Paysign, Inc. (PAYS) Q2 2021 Earnings Call Transcript
Revenue
$6.65M
▲ 3.2% YoY
Diluted EPS
$-0.02
Gross margin
47.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2021-05-12
Paysign, Inc. (PAYS) Q1 2021 Earnings Call Transcript
Revenue
$6.28M
▼ 40.6% YoY
Diluted EPS
$-0.03
▼ 200% YoY
Gross margin
45.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2021-03-25
Paysign, Inc. (PAYS) Q4 2020 Earnings Call Transcript
Revenue
$7.25M*
▼ 25.7% YoY
Gross margin
51.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY20 · Q3
2020-11-17
Paysign, Inc. (PAYS) Q3 2020 Earnings Call Transcript
Revenue
−$152,541
▼ 101.7% YoY
Diluted EPS
$-0.12
▼ 340% YoY
Gross margin
2251.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q2
2020-08-13
Paysign, Inc. (PAYS) Q2 2020 Earnings Call Transcript
Revenue
$6.44M
▼ 25.4% YoY
Diluted EPS
$0.00
▼ 100% YoY
Gross margin
51.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q1
2020-05-07
Paysign, Inc. (PAYS) Q1 2020 Earnings Call Transcript
Revenue
$10.58M
▲ 45.7% YoY
Diluted EPS
$0.03
▲ 50% YoY
Gross margin
54.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Showing 1–26 of 26 webcasts
Key facts CIK 1496443 CUSIP 70451A104 13F (30d) 25 filings 25 filers Visit website Investor relations